Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann. In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Thousands of potential cancer medicines in development
     
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine to fight breast cancer is currently in the pipeline. It targets the Bcl-2 protein, which appears to contribute…  
  • From 2007 to 2011, lung cancer incidence rates decreased by three percent each year in men and 2.2 percent each year in women.  
  • The standard treatment for prostate cancer used to require radical prostatectomy. Now, less invasive therapies like brachytherapy have been shown to have equal outcomes with fewer side effects.  
  • Following the current path, the prostate cancer incidence rate will increase by 75.4% (786,000) between 2003 and 2023. If an alternative path is taken, there will be 21.5% (393,000) fewer…